C.R. Bard (NYSE:BCR) has notified buyers of its LifeStream covered iliac stent of a higher-than-anticipated restenosis rate among patients. The field notice issued by Bard, parent company BD and Irish catheter-maker ClearStream Technologies said the restenosis rate of 0.04% exceeds the acceptable failure rate of 0.01%. An unspecified number of restenosis complaints was reported following implantation of […]
C.R. Bard
BD’s Bard reported to win third IVC bellwether
A federal jury in Arizona reportedly found for Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard today in a bellwether product liability case brought over its inferior vena cava filters. Although it’s the fourth bellwether case in the multi-district litigation over the IVC devices, which are designed to prevent blood clots from passing through the body’s […]
Judge pares claims in Bard IVC bellwether
A federal judge in Arizona yesterday pared some claims in the third bellwether case involving inferior vena cava filters made by Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard, as the trial entered its 11th day. It’s the fourth bellwether in the multi-district litigation over the IVC devices, which are designed to prevent blood clots from passing through […]
Appeals court overturns patent board in Bard spat with AngioDynamics
A federal court this week reversed a number of Patent Trial and Appeal Board rulings which invalidated patents held by Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard in an ongoing patent spat with AngioDynamics (NSDQ:ANGO) . The case involves three C.R. Bard medical device patents, which in previous proceedings had had 34 of 41 claims invalidated as anticipated […]
Missouri appeals court revives pelvic mesh suit against BD’s Bard
A Missouri state appeals court last week revived a pelvic mesh product liability lawsuit against Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard, ruling that a lower court was wrong to exclude prior verdicts that went against the company. Barad and co-defendant Boston Scientific (NYSE:BSX) escaped the suit in February 2016 after a Kansas City jury voted 10-2 […]
AngioDynamics nets a win in antitrust case against BD’s Bard
A federal judge in New York this week denied a motion from Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard to dismiss an antitrust lawsuit filed by AngioDynamics (NSDQ:ANGO) alleging unfair competition, according to an Albany Business Review report. AngioDynamics filed the suit against Bard last May, claiming that the larger company illegally ties the sales of its […]
Hologic CFO McMahon jumps ship to Agilent | Personnel Moves – August 1, 2018
Hologic (NSDQ:HOLX) said yesterday that its CFO Bob McMahon is leaving to take up a CFO role at Agilent Technologies. The Marlborough, Mass.-based company said that its current chief accounting officer Karleen Oberton has been lifted to CFO, effective today. “Bob has made tremendous contributions to Hologic over the last four years, and we wish him […]
BD’s Bard wins third IVC filter bellwether
Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard this week won a third inferior vena cava filter bellwether case after the statute of limitations expired on the claims, according to court documents. In the case, Bard faced allegations from plaintiff Carol Kruse claiming that it sold defective IVC blood filters intended to prevent pulmonary emboli. US District Judge […]
No new trial for Bard in $4m vena cava filter loss
Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard this week failed to win a new trial after a jury awarded nearly $4 million to the plaintiff in a bellwether product liability lawsuit brought over Bard’s inferior vena cava filter. Plaintiff Sherr-Una Booker was implanted in June 2007 with a Bard G2 IVC filter to mitigate her risk […]
BD lifts Bard vet DeFord to CTO | Personnel Moves – June 4, 2018
Becton Dickinson (NYSE:BDX) said last Friday it is lifting former C.R. Bard science, technology and clinical affairs senior VP John DeFord to the role of chief technology officer and exec VP. Since acquiring Bard in a $24 billion deal that closed last December, DeFord has served as BD interventional segment R&D SVP, the Franklin Lakes, N.J.-based company […]
BD beats The Street with Q2 results
Shares in Becton Dickinson (NYSE: BDX) held steady today after the company beat expectations on Wall Street with its second-quarter results. The Franklin Lakes, N.J.-based company swung to a net loss of -$50 million, or -19¢ per share, on sales of $4.22 billion for the 3 months ended March 31, up 42% compared with the same period […]